An exploration of how illicit compounding intersects with patent protections, market exclusivity, and the proposed EU pharma package revisions shaping the future of pharmaceutical innovation.
Speaker(s):
Raquel Frisardi
Senior Corporate Counsel
Novo Nordisk
Session Type:
Panel